ketoconazole has been researched along with Agranulocytosis in 16 studies
1-acetyl-4-(4-{[2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy}phenyl)piperazine : A dioxolane that is 1,3-dioxolane which is substituted at positions 2, 2, and 4 by imidazol-1-ylmethyl, 2,4-dichlorophenyl, and [para-(4-acetylpiperazin-1-yl)phenoxy]methyl groups, respectively.
Agranulocytosis: A decrease in the number of GRANULOCYTES; (BASOPHILS; EOSINOPHILS; and NEUTROPHILS).
| Excerpt | Relevance | Reference |
|---|---|---|
| "The present study evaluated the activity of ketoconazole in neutropenic dogs with systemic candidiasis." | 7.67 | Treatment of systemic candidiasis in neutropenic dogs with ketoconazole. ( Epstein, RB; Gawith, KE; Keppen, M; Weber, MJ, 1985) |
| " There is a clear need to obtain quick information on itraconazole plasma levels in order to adapt dosage during prophylactic treatment in immunocompromised patients." | 5.28 | Antifungal prophylaxis with itraconazole in prolonged neutropenia: correlation with plasma levels. ( Boogaerts, MA; De Beule, K; Demuynck, H; Verbist, L; Verhoef, GE; Zachee, P, 1989) |
| "We compared the efficacies of the new triazole antifungal drugs fluconazole and itraconazole with that of amphotericin B in vitro and in an animal model of systemic candidiasis in normal and neutropenic mice." | 3.67 | Comparison of the efficacies of amphotericin B, fluconazole, and itraconazole against a systemic Candida albicans infection in normal and neutropenic mice. ( Mattie, H; van Furth, R; Van t Wout, JW, 1989) |
| "The present study evaluated the activity of ketoconazole in neutropenic dogs with systemic candidiasis." | 3.67 | Treatment of systemic candidiasis in neutropenic dogs with ketoconazole. ( Epstein, RB; Gawith, KE; Keppen, M; Weber, MJ, 1985) |
| " Bioavailability of ketoconazole was unpredictable." | 2.67 | Amphotericin B vs high-dose ketoconazole for empirical antifungal therapy among febrile, granulocytopenic cancer patients. A prospective, randomized study. ( Browne, M; Cotton, D; Gress, J; Hathorn, J; Marshall, D; McKnight, J; Rubin, M; Skelton, J; Thaler, M; Walsh, TJ, 1991) |
| "Ketoconazole was administered in a 200 mg dose twice daily." | 2.66 | A randomized trial comparing ketoconazole and nystatin prophylactic therapy in neutropenic patients. ( Malcom, LG; Vogler, WR; Winton, EF, 1987) |
| "Ketoconazole was better tolerated and more effective than nystatin in reducing colonization due to Candida species but was also associated with significantly increased rates of colonization with T." | 2.66 | Comparative trial of ketoconazole and nystatin for prevention of fungal infection in neutropenic patients treated in a protective environment. ( Klosterman, A; Meyers, JD; Shepp, DH; Siegel, MS, 1985) |
| "Ketoconazole or miconazole was randomly administered to 42 and 46 neutropenic patients respectively." | 2.65 | Oral prophylaxis with miconazole or ketoconazole of invasive fungal disease in neutropenic cancer patients. ( Cruciani, M; Klastersky, J; Meunier-Carpentier, F, 1983) |
| "Ketoconazole was better tolerated than nystatin and neither drug caused toxic effects." | 2.65 | Efficacy of ketoconazole v nystatin in prevention of fungal infections in neutropenic patients. ( Bergman, AG; Jones, PG; Kauffman, CA; Liepman, MK; McAuliffe, LS, 1984) |
| " There is a clear need to obtain quick information on itraconazole plasma levels in order to adapt dosage during prophylactic treatment in immunocompromised patients." | 1.28 | Antifungal prophylaxis with itraconazole in prolonged neutropenia: correlation with plasma levels. ( Boogaerts, MA; De Beule, K; Demuynck, H; Verbist, L; Verhoef, GE; Zachee, P, 1989) |
| "Candidiasis was established by intravenously administering Candida albicans or Candida tropicalis (1-2 x 10(5) colony-forming units) and resulted in hepatic and splenic lesions that mimicked those associated with hepatosplenic candidiasis in humans." | 1.27 | Evaluation of single-drug and combination antifungal therapy in an experimental model of candidiasis in rabbits with prolonged neutropenia. ( Bacher, J; O'Leary, T; Pizzo, PA; Thaler, M, 1988) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 13 (81.25) | 18.7374 |
| 1990's | 3 (18.75) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Meunier-Carpentier, F | 2 |
| Cruciani, M | 1 |
| Klastersky, J | 1 |
| Brincker, H | 1 |
| Jones, PG | 1 |
| Kauffman, CA | 1 |
| McAuliffe, LS | 1 |
| Liepman, MK | 1 |
| Bergman, AG | 1 |
| van't Wout, JW | 1 |
| Novakova, I | 1 |
| Verhagen, CA | 1 |
| Fibbe, WE | 1 |
| de Pauw, BE | 1 |
| van der Meer, JW | 1 |
| Walsh, TJ | 1 |
| Rubin, M | 1 |
| Hathorn, J | 1 |
| Gress, J | 1 |
| Thaler, M | 2 |
| Skelton, J | 1 |
| McKnight, J | 1 |
| Browne, M | 1 |
| Marshall, D | 1 |
| Cotton, D | 1 |
| Wolf, HH | 1 |
| Scharf, RE | 1 |
| Arning, M | 1 |
| Schneider, W | 1 |
| Van t Wout, JW | 1 |
| Mattie, H | 1 |
| van Furth, R | 1 |
| Boogaerts, MA | 1 |
| Verhoef, GE | 1 |
| Zachee, P | 1 |
| Demuynck, H | 1 |
| Verbist, L | 1 |
| De Beule, K | 2 |
| Ninane, J | 1 |
| Sluysmans, T | 1 |
| Vermylen, C | 1 |
| Woestenborghs, R | 1 |
| Cauwenbergh, G | 1 |
| Cornu, G | 1 |
| Koletzko, B | 1 |
| Wendel, U | 1 |
| Bremer, HJ | 1 |
| Bacher, J | 1 |
| O'Leary, T | 1 |
| Pizzo, PA | 1 |
| von Paleske, A | 1 |
| Müllerleile, U | 1 |
| Gressler, V | 1 |
| Garbrecht, M | 1 |
| Hossfeld, DK | 1 |
| Vogler, WR | 1 |
| Malcom, LG | 1 |
| Winton, EF | 1 |
| Weber, MJ | 1 |
| Keppen, M | 1 |
| Gawith, KE | 1 |
| Epstein, RB | 1 |
| Shepp, DH | 1 |
| Klosterman, A | 1 |
| Siegel, MS | 1 |
| Meyers, JD | 1 |
8 trials available for ketoconazole and Agranulocytosis
| Article | Year |
|---|---|
Oral prophylaxis with miconazole or ketoconazole of invasive fungal disease in neutropenic cancer patients.
Topics: Agranulocytosis; Antifungal Agents; Candidiasis; Drug Combinations; Female; Humans; Imidazoles; Keto | 1983 |
Prophylaxis of fungal infections in neutropenic cancer patients.
Topics: Agranulocytosis; Amphotericin B; Aspergillosis; Candidiasis; Clinical Trials as Topic; Humans; Ketoc | 1983 |
Efficacy of ketoconazole v nystatin in prevention of fungal infections in neutropenic patients.
Topics: Adult; Agranulocytosis; Female; Humans; Ketoconazole; Male; Middle Aged; Mycoses; Neutropenia; Nysta | 1984 |
[Therapy of systemic mycoses in neutropenic patients using itraconazole. A comparative, randomized study with amphotericin B].
Topics: Adolescent; Agranulocytosis; Amphotericin B; Antifungal Agents; Aspergillosis, Allergic Bronchopulmo | 1991 |
Amphotericin B vs high-dose ketoconazole for empirical antifungal therapy among febrile, granulocytopenic cancer patients. A prospective, randomized study.
Topics: Adult; Agranulocytosis; Amphotericin B; Fever; Humans; Immune Tolerance; Ketoconazole; Mycoses; Neop | 1991 |
Itraconazole versus ketoconazole for the prophylaxis of fungal infection in neutropenic children: results of two consecutive nonrandomized studies.
Topics: Adolescent; Agranulocytosis; Antifungal Agents; Child; Child, Preschool; Clinical Trials as Topic; F | 1989 |
A randomized trial comparing ketoconazole and nystatin prophylactic therapy in neutropenic patients.
Topics: Acute Disease; Adolescent; Adult; Aged; Agranulocytosis; Candidiasis, Oral; Female; Humans; Immune T | 1987 |
Comparative trial of ketoconazole and nystatin for prevention of fungal infection in neutropenic patients treated in a protective environment.
Topics: Agranulocytosis; Candida albicans; Candidiasis; Clinical Trials as Topic; Environment, Controlled; H | 1985 |
8 other studies available for ketoconazole and Agranulocytosis
| Article | Year |
|---|---|
Prevention of mycosis in granulocytopenic patients with prophylactic ketoconazole treatment.
Topics: Acute Disease; Adult; Agranulocytosis; Antifungal Agents; Candidiasis, Cutaneous; Double-Blind Metho | 1983 |
Preliminary results of treatment with itraconazole in patients with systemic fungal infections.
Topics: Acute Disease; Adult; Agranulocytosis; Antifungal Agents; Antineoplastic Agents; Drug Evaluation; Dr | 1990 |
Comparison of the efficacies of amphotericin B, fluconazole, and itraconazole against a systemic Candida albicans infection in normal and neutropenic mice.
Topics: Agranulocytosis; Amphotericin B; Animals; Antifungal Agents; Candida albicans; Candidiasis; Fluconaz | 1989 |
Antifungal prophylaxis with itraconazole in prolonged neutropenia: correlation with plasma levels.
Topics: Adult; Aged; Agranulocytosis; Antifungal Agents; Female; Humans; Itraconazole; Ketoconazole; Male; M | 1989 |
Lithium for treatment of neutropenia in glycogen storage disease type Ib.
Topics: Agranulocytosis; Chlorides; Drug Combinations; Drug Therapy, Combination; Female; Glycogen Storage D | 1986 |
Evaluation of single-drug and combination antifungal therapy in an experimental model of candidiasis in rabbits with prolonged neutropenia.
Topics: Agranulocytosis; Amphotericin B; Animals; Antifungal Agents; Candidiasis; Cytarabine; Drug Evaluatio | 1988 |
Incidence and treatment of fungal infections in neutropenic patients.
Topics: Agranulocytosis; Amphotericin B; Female; Humans; Ketoconazole; Leukemia, Lymphoid; Leukemia, Myeloid | 1987 |
Treatment of systemic candidiasis in neutropenic dogs with ketoconazole.
Topics: Agranulocytosis; Animals; Bone Marrow; Bone Marrow Transplantation; Candida albicans; Candidiasis; D | 1985 |